Optimizing Hcc Treatment With Predicative

Changhoon Yoo, MD, PhD, Asan Medical Center, Seoul, Republic of Korea, describes current areas of unmet need in ...

Richard S. Finn, MD, Robin K. (“Katie”) Kelley, MD, and Laura M. Kulik, MD, discuss

David J. Pinato, MD, PhD, clinical senior lecturer in medical oncology, clinician scientist, consultant medical oncologist, ...

Further considerations for selecting lenvatinib, sorafenib, or Y-90 are provided in the context of frontline systemic

Experts discuss

Richard S. Finn, MD, and Anthony El-Khoueiry, MD, discuss changes to the

A global perspective on the current

... important aspect of the

David Pinato, MD, PhD, Imperial College London, London, UK, discusses bridging techniques to improve the chances of curative ...

Stephen Lam Chan, MBBS, Chinese University of Hong Kong, Hong Kong, China, discusses the current

Daneng Li, MD, City of Hope National Medical Center, Duarte, CA, explores developments in

There have been tremendous advancements in the multidisciplinary management of GI cancers in the past decade, with a ...

An examination of surgical candidacy in patients, and an overview of the available

Practice-Changing Updates in Different Settings of Advanced

Ghassan K. Abou-Alfa, MD, reviews the details of a case of a 70-year-old man with metastatic

Changhoon Yoo, MD, PhD, Asan Medical Center, Seoul, Republic of Korea, discusses the impact of immune checkpoint inhibitors ...

Join the Oncology Brothers, Drs. Rahul and Rohit Gosain, in this engaging podcast episode as they delve into the

An in-depth analysis of data supporting lenvatinib versus sorafenib for the

Jeff Geschwind, MD, describes the 2 primary forms of embolization used as a local/regional approach to

Chair, Richard S. Finn, MD, Ahmed Omar Kaseb, MD, CMQ, and Stacey M. Stein, MD, discuss